Clinical trials: Hypersensitivity
Asthma
Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) Therapy
The aim of the study is to assess and compare efficacy and safety of BI 54903 at 3 doses twice daily (b.i.d.) and fluticasone propionate hydrofluoroalkane metered dose inhaler (HFA MDI) at a dose of 88 mcg b.i.d and placebo…
- Trial name
- NCT01397162
- Testing
- Fluticasone propionate, BI 54903
- Where
- 41 sites in United States
- Volunteers
- 29 people
- Sponsor
- Boehringer Ingelheim
Sarcoidosis
Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis
The purpose of this research study to find out if a drug called OctreoScan or DOTATATE can help doctors diagnose people with cardiac sarcoidosis better. OctreoScan and DOTATATE are both approved by the U.S.
- Trial name
- NCT02546388
- Testing
- Indium-111 Pentreotide, Gallium-68 DOTATATE
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Marcelo F. Di Carli, MD, FACC
Asthma
Comparing the Efficacy of Bricanyl M2 and Bricanyl M3 at 0.5 and 1.5 mg Dose Levels, to Allow for a Switch From Bricanyl Turbuhaler M2 to Bricanyl Turbuhaler M3
A randomised, double-blind, double-dummy, multi-site, phase III, single dose, 4-way cross-over pharmacodynamic study evaluating the efficacy of Bricanyl Turbuhaler M3 compared to Bricanyl Turbuhaler M2 by studying the protective…
- Trial name
- NCT02322788
- Testing
- Terbutaline sulphate
- Where
- 4 sites in Canada, Netherlands and 1 more
- Volunteers
- 95 people
- Sponsor
- AstraZeneca
Atopic Dermatitis
Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis
This is an open-label, single arm study of 52 weeks duration. The study will assess the safety and efficacy of lebrikizumab in adolescent participants (≥12 to <18 years weighing ≥40 kilograms) with moderate-to-severe atopic…
- Trial name
- ADore (NCT04250350)
- Testing
- Lebrikizumab
- Where
- 70 sites in United States, Australia and 2 more
- Volunteers
- 206 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis
Improvement In Scratch Behavior And Sleep In Patients With Atopic Dermatitis
This single blind study is to primarily evaluate wearable devices and Observer Reported Itch Assessment in children to assess reduction of itch and night-time scratch in response to Crisaborole treatment vs.
- Trial name
- PAD (NCT05200403)
- Testing
- Crisaborole 2%, Vehicle treatment, Accelerometry device for children
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Boston University
Asthma
Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)
This is a variable length study to evaluate the efficacy and safety of budesonide/glycopyrronium/formoterol inhaler in adults and adolescents with severe asthma inadequately controlled with standard of care
- Trial name
- KALOS (NCT04609878)
- Testing
- BGF MDI 320/28.8/9.6 μg, BGF MDI 320/14.4/9.6 μg, BFF MDI 320/9.6 μg
- Where
- 360 sites in United States, Argentina and 19 more
- Volunteers
- 2,274 people
- Sponsor
- AstraZeneca
Rhinitis, Asthma
The Safety and Efficacy of Intralymphatic Immunotherapy in Pollen Allergic Adolescents and Young Adults With Asthma
The study evaluates the safety and efficacy of intralymphatic allergen-specific immunotherapy given to adolescents and young adults who are allergic to grass or birch pollen and have mild or moderate asthma.
- Conditions
- Rhinitis, Asthma, Allergy
- Trial name
- NCT03394508
- Testing
- ALK Alutard birch or 5-grasses, ALK diluent 0,3% human albumin
- Volunteers
- 30 people
- Sponsor
- Karolinska Institutet
Peanut Hypersensitivity, Food Hypersensitivity
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Sublingual/Oral Immunotherapy for the Treatment of Peanut Allergy
The purpose of this study is to explore the safety and efficacy of a sublingual (under the tongue) immunotherapy (SLIT) dosing regimen and an oral immunotherapy (OIT) regimen in inducing desensitization and long term tolerance in…
- Conditions
- Peanut Hypersensitivity, Food Hypersensitivity, Immediate Hypersensitivity
- Trial name
- NCT01084174
- Testing
- Peanut powder, Peanut extract
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Johns Hopkins University
Asthma
Safety Study of the Effects of Inhaled Fluticasone Furoate/GW642444 on the Hypothalamic-Pituitary-Adrenal (HPA) Axis
The purpose of this study is to assess the effect of six weeks' treatment with two once-daily strengths of Fluticasone Furoate/GW642444 Inhalation Powder on the HPA axis system
- Trial name
- NCT01086410
- Testing
- Fluticasone Furoate/GW642444 Inhalation Powder, Prednisolone Oral Capsule
- Where
- 17 sites in United States, Germany and 1 more
- Volunteers
- 185 people
- Sponsor
- GlaxoSmithKline
Hereditary Angioedema (HAE)
Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE)
The purpose of this study is to determine if a subcutaneous dose of DX-88 (ecallantide; an investigational product) is safe and relieves symptoms of HAE in patients suffering from moderate to severe acute attacks of HAE.
- Trial name
- NCT00262080
- Testing
- ecallantide, Phosphate Buffer Saline (PBS),
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Shire
Asthma
Efficacy, Safety and Pharmacokinetics of Indacaterol Acetate in Patients With Persistent Asthma
To provide the efficacy, safety and pharmacokinetics of indacaterol acetate in patients with persistent asthma to support dose selection of indacaterol in fixed dose combination QMF149.
- Trial name
- NCT01609478
- Testing
- indacaterol, mometasone furoate
- Where
- 96 sites in Bulgaria, Canada and 6 more
- Volunteers
- 335 people
- Sponsor
- Novartis Pharmaceuticals
Rhinitis, Allergic, Perennial
Study FFR116364, a Placebo-controlled Study of GW685698X in Paediatric Subjects With Perennial Allergic Rhinitis
Efficacy and safety of GW685698X (55 µg/day, q.d.) nasal spray over a period of 2 weeks in Japanese paediatric subjects ages 6 to < 15 years with perennial allergic rhinitis will be evaluated compared with placebo.
- Trial name
- NCT01630135
- Testing
- Fluticasone furoate
- Where
- 22 sites in Japan
- Volunteers
- 261 people
- Sponsor
- GlaxoSmithKline
Barrett's Esophagus, Eosinophilic Esophagitis
Study to Image the Esophagus Using the OFDI Capsule
The main purpose of this research is to test the feasibility and tolerability of the tethered capsule Optical Frequency Domain Imaging (OFDI)
- Trial name
- NCT02204150
- Testing
- OFDI Capsule
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Asthma, Aspirin-Induced
Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD)
The purpose of this phase 2 study is to assess the safety and efficacy of oral ifetroban for the treatment of aspirin-exacerbated respiratory disease (AERD).
- Trial name
- NCT03028350
- Testing
- Ifetroban Oral Capsule
- Where
- 16 sites in United States
- Volunteers
- 54 people
- Sponsor
- Cumberland Pharmaceuticals
Non Small Cell Lung Cancer
Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer
This is a Phase I, open-label, 2-part study in patients with a confirmed diagnosis of epidermal growth factor receptor (EGFR) mutation positive (EGFRm+) non-small cell lung cancer (NSCLC), who have progressed following prior…
- Trial name
- NCT02317016
- Testing
- Pharmacokinetic sampling - AZD9291, AZD9291 tablet dosing, Rosuvastatin
- Where
- 13 sites in United States, France and 2 more
- Volunteers
- 44 people
- Sponsor
- AstraZeneca
Chronic Spontaneous Urticaria
A Study to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO)
The purpose of this study is to investigate the use of benralizumab is effective in the treatment of chronic spontaneous urticaria (CSU) who are symptomatic despite the use of antihistamines.
- Trial name
- ARROYO (NCT04612725)
- Testing
- Benralizumab
- Where
- 40 sites in United States, Bulgaria and 5 more
- Volunteers
- 159 people
- Sponsor
- AstraZeneca
Asthma
Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II
The aim of this trial is to evaluate the efficacy and safety of 2.5 and 5 mcg tiotropium over a 24-week treatment period as compared to placebo and salmeterol (50 mcg twice daily).
- Trial name
- NCT01172821
- Testing
- tiotropium Respimat® low dose, tiotropium Respimat® high dose, 50 mcg salmeterol HFA MDI
- Where
- 125 sites in United States, Brazil and 9 more
- Volunteers
- 1,032 people
- Sponsor
- Boehringer Ingelheim
Asthma
Treatment Of Symptomatic Asthma In Children
This study is being conducted to investigate whether in childhood salmeterol/ fluticasone propionate 50/100 bd delivered via the Diskus® inhaler and fluticasone propionate 200 mcg bd delivered via the Diskus® inhaler are non…
- Trial name
- NCT00197106
- Testing
- Salmeterol/ fluticasone propionate Diskus® inhaler 50/100 mcg, fluticasone propionate 2 x 100 mcg
- Where
- 18 sites in Netherlands
- Volunteers
- 176 people
- Sponsor
- GlaxoSmithKline
Allergic Rhinitis
Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Allergic Rhinitis (Study P05583)
This study seeks to prospectively demonstrate that Nasonex is better than placebo in relieving nasal congestion in patients with seasonal allergic rhinitis.
- Trial name
- NCT00728416
- Testing
- Mometasone furoate nasal spray (MFNS)
- Volunteers
- 333 people
- Sponsor
- Organon and Co
Asthma, Aspirin-Induced, Chronic Rhinosinusitis With Nasal Polyps
Aggravated Airway Inflammation: Research on Biological Treatment (Mepolizumab)
Primary objective: to investigate the efficacy of Mepolizumab 100 milligram (mg) every month compared to placebo in reducing validated Sinonasal Outcome Test -22 score and on reducing endoscopic Nasal Polyp Score.
- Trial name
- AirGOs-biol (NCT04823585)
- Testing
- Mepolizumab
- Where
- Finland
- Volunteers
- 95 people
- Sponsor
- Helsinki University Central Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.